These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

719 related items for PubMed ID: 27165711

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Büller HR, Choi Y, Gallus A, Grosso MA, Middeldorp S, Oh D, Raskob G, Schwocho L, Cohen AT.
    Thromb Haemost; 2016 Jul 04; 116(1):155-61. PubMed ID: 27010092
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A, Giugliano RP, Ruff CT, Nordio F, Gogia HS, Awasty VR, Henderson DA, Mercuri MF, Rutman H, Antman EM, Braunwald E.
    Am Heart J; 2016 Feb 04; 172():144-51. PubMed ID: 26856226
    [Abstract] [Full Text] [Related]

  • 10. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
    Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M, Hokusai-VTE Investigators.
    J Thromb Haemost; 2013 Jul 04; 11(7):1287-94. PubMed ID: 23574579
    [Abstract] [Full Text] [Related]

  • 11. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR, Hokusai-VTE investigators.
    Lancet Haematol; 2016 Aug 04; 3(8):e379-87. PubMed ID: 27476789
    [Abstract] [Full Text] [Related]

  • 12. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
    Di Nisio M, Raskob G, Büller HR, Grosso MA, Zhang G, Winters SM, Cohen A.
    Thromb Haemost; 2017 Apr 03; 117(4):784-793. PubMed ID: 28151543
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Kurtoglu M, Koksoy C, Hasan E, Akcalı Y, Karabay O, Filizcan U, TROMBOTEK Study Group.
    J Vasc Surg; 2010 Nov 03; 52(5):1262-70. PubMed ID: 20732787
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
    Nelson SE, Giugliano RP, Antman EM, Park JG, Norden AD, Rost NS, Silverman S, Singhal AB, Lanz HJ, Braunwald E, Ruff CT, ENGAGE AF-TIMI 48 Steering Committee and Investigators.
    J Clin Neurosci; 2021 Apr 03; 86():294-300. PubMed ID: 33446422
    [Abstract] [Full Text] [Related]

  • 18. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP, Ruff CT, Rost NS, Silverman S, Wiviott SD, Lowe C, Deenadayalu N, Murphy SA, Grip LT, Betcher JM, Duggal A, Dave J, Shi M, Mercuri M, Antman EM, Braunwald E, ENGAGE AF-TIMI 48 Investigators.
    Stroke; 2014 Aug 03; 45(8):2372-8. PubMed ID: 24947287
    [Abstract] [Full Text] [Related]

  • 19. Multicenter, Open-Label, Randomized Controlled Trial of Warfarin and Edoxaban Tosilate Hydrate for the Treatment of Deep Vein Thrombosis in Persons with Severe Motor Intellectual Disabilities.
    Ohmori H, Nakamura M, Kada A, Saito AM, Sanayama Y, Shinagawa T, Fujita H, Wakisaka A, Maruhashi K, Okumura A, Takizawa N, Murata H, Inoue M, Kaneko H, Taniguchi H, Kawasaki M, Sano N, Akaboshi S, Tanuma N, Sone S, Kumode M, Takechi T, Koretsune Y, Sumimoto R, Miyanomae T.
    Kurume Med J; 2018 Dec 21; 65(1):11-16. PubMed ID: 30158356
    [Abstract] [Full Text] [Related]

  • 20. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
    Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, Shi M, Mercuri M, Antman EM, Braunwald E.
    J Am Heart Assoc; 2016 Feb 23; 5(2):. PubMed ID: 26908401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.